➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Dow
Johnson and Johnson
Merck
Colorcon

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Acetamide

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Acetamide?

Acetamide is an investigational drug.

There have been 14 clinical trials for Acetamide. The most recent clinical trial was a Phase 2 trial, which was initiated on August 15th 2018.

The most common disease conditions in clinical trials are Depressive Disorder, Schizophrenia, and Inflammation. The leading clinical trial sponsors are California Pacific Medical Center Research Institute, St. Michael's Hospital, Toronto, and Weill Medical College of Cornell University.

There is one US patent protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Acetamide
TitleSponsorPhase
Senicapoc and Dehydrated StomatocytosisQuest DiagnosticsPhase 3
Senicapoc and Dehydrated StomatocytosisBoston Children’s HospitalPhase 3
Modafinil's Effects on Cognition in Remitted MDDOntario Ministry of Health and Long Term CarePhase 3

See all Acetamide clinical trials

Clinical Trial Summary for Acetamide

Top disease conditions for Acetamide
Top clinical trial sponsors for Acetamide

See all Acetamide clinical trials

US Patents for Acetamide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Acetamide   Start Trial Efficient and scalable synthesis of 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs ARIAGEN, INC. (Menlo Park, CA)   Start Trial
Acetamide   Start Trial Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity CuRNA, Inc. (Miami, FL)   Start Trial
Acetamide   Start Trial Conductive fibrous materials Agency for Science, Technology and Research (Singapore, SG)   Start Trial
Acetamide   Start Trial Anti-inflammatory agents Resverlogix Corp. (Calgary, Alberta, CA)   Start Trial
Acetamide   Start Trial P38 MAP kinase inhibitors Respivert Ltd. (Buckinghamshire, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Acetamide

Drugname Country Document Number Estimated Expiration Related US Patent
Acetamide Australia AU2013234499 2032-03-17   Start Trial
Acetamide Canada CA2867494 2032-03-17   Start Trial
Acetamide China CN104284891 2032-03-17   Start Trial
Acetamide Denmark DK2836485 2032-03-17   Start Trial
Acetamide European Patent Office EP2836485 2032-03-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Dow
Johnson and Johnson
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.